Elanco Animal Health Incorporated Business Combination, Acquisition Related Costs
Elanco Animal Health Incorporated (ELAN) reported Business Combination, Acquisition Related Costs of $18.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2025-02-25
- Elanco Animal Health Incorporated business combination, acquisition related costs for the quarter ending 2023-12-31 was $7.00M, a 75.00% decline year-over-year.
- Elanco Animal Health Incorporated business combination, acquisition related costs for the quarter ending 2023-09-30 was $11.00M, a 59.26% decline year-over-year.
- Elanco Animal Health Incorporated business combination, acquisition related costs for the quarter ending 2023-06-30 was $35.00M, a 34.62% increase year-over-year.
- Elanco Animal Health Incorporated business combination, acquisition related costs for the quarter ending 2022-12-31 was $28.00M.
- Elanco Animal Health Incorporated business combination, acquisition related costs for fiscal 2024 was $18.00M, a 80.65% decline from fiscal 2023.
- Elanco Animal Health Incorporated business combination, acquisition related costs for fiscal 2023 was $93.00M, a 11.43% decline from fiscal 2022.
- Elanco Animal Health Incorporated business combination, acquisition related costs for fiscal 2022 was $105.00M, a 35.19% decline from fiscal 2021.
- Elanco Animal Health Incorporated business combination, acquisition related costs for fiscal 2021 was $162.00M.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|
| 2024-12-31 | $18.00M 10-K · filed 2025-02-25 | |||
| 2023-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $18.00M derived: sum of 2 quarters · filed 2025-02-25 | $53.00M derived: sum of 3 quarters · filed 2025-02-25 | $93.00M 10-K · filed 2025-02-25 |
| 2023-09-30 | $11.00M 10-Q · filed 2023-11-07 | $46.00M derived: sum of 2 quarters · filed 2023-11-07 | $86.00M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $35.00M 10-Q · filed 2023-08-07 | $75.00M 10-Q · filed 2023-08-07 | ||
| 2022-12-31 | $28.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $55.00M derived: sum of 2 quarters · filed 2025-02-25 | $81.00M derived: sum of 3 quarters · filed 2025-02-25 | $105.00M 10-K · filed 2025-02-25 |
| 2022-09-30 | $27.00M 10-Q · filed 2023-11-07 | $53.00M derived: sum of 2 quarters · filed 2023-11-07 | $77.00M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $26.00M 10-Q · filed 2023-08-07 | $50.00M 10-Q · filed 2023-08-07 | ||
| 2021-12-31 | $162.00M 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |